Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 7/20 | 0.47 |
| ▸ | DRD4 | P21917 | 7/20 | 0.47 |
| ▸ | DRD3 | P35462 | 7/20 | 0.47 |
| ▸ | UBE2M | P61081 | 1/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL882579 | 1.00 | S1PR5 (0.48) | S1PR5S1PR1DRD2DRD4DRD3 | |
| SCHEMBL875727 | 1.00 | S1PR5 (0.48) | S1PR5S1PR1DRD2DRD4DRD3 | |
| SCHEMBL875284 | 1.00 | S1PR5 (0.48) | S1PR5S1PR1DRD2DRD4DRD3 | |
| SCHEMBL6232439 | 0.91 | S1PR5 (0.53) | S1PR5S1PR1FUCA1SIGMAR1 | |
| SCHEMBL585357 | 0.91 | S1PR5 (0.53) | S1PR5S1PR1FUCA1SIGMAR1 | |
| SCHEMBL585358 | 0.91 | S1PR5 (0.53) | S1PR5S1PR1FUCA1SIGMAR1 | |
| SCHEMBL6232433 | 0.91 | S1PR5 (0.53) | S1PR5S1PR1FUCA1SIGMAR1 | |
| SCHEMBL1282973 | 0.88 | S1PR5 (0.53) | S1PR5DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL19064205 | 0.87 | S1PR5 (0.52) | S1PR5S1PR1FUCA1SIGMAR1 | |
| SCHEMBL9112639 | 0.87 | S1PR5 (0.52) | S1PR5S1PR1FUCA1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141852-A1 | CDK2 INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF | 益方生物科技(上海)股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3181566-A1 | IMIDAZOTRIAZINONE COMPOUNDS | Ironwood Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170152265-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-05-25 | — | — | US | disclosed |
| US-9624243-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-9540380-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2619208-B1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2152712-A1 | AMINO-HETEROCYCLIC COMPOUNDS | Pfizer Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | disclosed |
| WO-2008139293-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | AGTR2, AGTR1, BDKRB2 | S1PR5 859/4885S1PR1 849/4885DRD2 356/4885 |
| US-20170152265-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | S1PR5 1963/4885S1PR1 2397/4885DRD2 3928/4885 |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE12, PDE4A | S1PR5 1335/4885S1PR1 1663/4885DRD2 3800/4885 |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | S1PR5 3767/4885S1PR1 3298/4885DRD2 181/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | S1PR5 906/4885S1PR1 1291/4885DRD2 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.